BMN-255
- Generic Name
- BMN-255
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
Phase 1
Withdrawn
- Conditions
- Kidney StoneHyperoxaluriaNonalcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT06138327
- Locations
- 🇺🇸
University of Alabama - Department of Urology, Birmingham, Alabama, United States
🇺🇸ProSciento, Inc., Chula Vista, Florida, United States
🇺🇸Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath